18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma

Annals of Surgical Oncology

Volumn 13, Issue 5, 2006, Pages 677-684

  Port, Elisa Rush ^a   Yeung, Henry ^a   Gonen, Mithat ^a   Liberman, Laura ^a   Caravelli, James ^a   Borgen, Patrick ^a   Larson, Steven ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18F 2 fluoro 2 deoxy D glucose positron emission tomography; Breast cancer; Extent of disease; High risk

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BREAST BIOPSY; BREAST CARCINOMA; BREAST SURGERY; CANCER CENTER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FALSE NEGATIVE RESULT; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METASTASIS; PATIENT SELECTION; PELVIS RADIOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SURGEON; THORAX RADIOGRAPHY; TUMOR BIOPSY; UNITED STATES; BONE TUMOR; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MIDDLE AGED; PATIENT SATISFACTION; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33645882958     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.03.035     Document Type: Article

References (18)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin 2005; 55:10-30.
2. Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005; 16:263-6.
3. Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999; 134:551-3; discussion 554.
4. NCCN Practice Guidelines in Oncology, Vol 1. 2005.
5. Warburg O. The Metabolism of Tumors. New York: Smith, 1931; 129-69.
6. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22:3805-12.
7. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90:620-5.
8. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am 2005; 43:1-21, ix.
9. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-70.
10. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71:3920-5.
11. Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early-stage breast cancer. Ann Surg Oncol 2004; 11:846-53.
12. Crippa F, Agresti R, Donne VD, et al. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan. Tumori 1997; 83:542-3.
13. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220-7.
14. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22:277-85.
15. Ciatto S, Pacini P, Azzini V, et al. Preoperative staging of primary breast cancer. A multicentric study. Cancer 1988; 61:1038-40.
16. Myers RE, Johnston M, Pritchard K, Levine M, Oliver T. Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline. CM AJ 2001; 164:1439-44.
17. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004; 22:1253-9.
18. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351-8.